Hypofractionated concurrent chemoradiation in non-small cell lung cancer (NSCLC): efficacy and toxicity of the SOCCAR trial regime in real world practice

被引：1
|
作者：
Iqbal, M. S. [1 ]
Vashisht, G. [2 ]
Mulvenna, P. [1 ]
McDonald, F. [1 ]
Turnbull, H. [1 ]
Atherton, P. [1 ]
Bradshaw, A. [1 ]
Simmons, T. [3 ]
Kovarik, J. [1 ]
Singhal, S. [1 ]
McMenemin, R. [3 ]
Greystoke, A. [4 ]
机构：
[1] Northern Ctr Canc Care, Clin Oncol, Newcastle Upon Tyne, Tyne & Wear, England
[2] Newcastle Univ, Med Sch, HH, Newcastle Upon Tyne, Tyne & Wear, England
[3] Freeman Rd Hosp, NCCC, Clin Oncol, Newcastle Upon Tyne, Tyne & Wear, England
[4] NCCC, Med Oncol, Newcastle Upon Tyne, Tyne & Wear, England
来源：
LUNG CANCER | 2018年 / 115卷
关键词：
D O I：
10.1016/S0169-5002(18)30175-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
149
引用
收藏
页码：S64 / S64
页数：1
相关论文
共 50 条
  • [31] Hypofractionated irradiation for non-small cell lung cancer
    Abratt, RP
    Bogart, JA
    Hunter, A
    LUNG CANCER, 2002, 36 (03) : 225 - 233
  • [32] Randomized phase III trial of concurrent chemoradiation followed by nivolumab or placebo for locally advanced non-small cell lung cancer (NSCLC) (RTOG 3505).
    Gerber, David E.
    Urbanic, James John
    Langer, Corey J.
    Hu, Chen
    Chang, I-Fen
    Lu, Bo
    Movsas, Benjamin
    Jeraj, Robert
    Curran, Walter John
    Bradley, Jeffrey D.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [33] Clinical prediction for acute toxicity in patients with locally advanced non-small cell lung cancer receiving concurrent chemoradiation
    Uyterlinde, W.
    Van den Heuvel, M.
    Van Werkhoven, E.
    Belderbos, J.
    Baas, P.
    Kwint, M.
    Knegjens, J.
    LUNG CANCER, 2012, 75 : S50 - S50
  • [34] Hypofractionated Concurrent Chemoradiation in Stage III Non-small Cell Lung Cancer: Does Planning Target Volume Size Correlate With Prognosis?
    Iqbal, M. S.
    Greystoke, A.
    Byrne, J.
    CLINICAL ONCOLOGY, 2019, 31 (06) : 402 - 403
  • [35] HYPOFRACTIONATED RADIOTHERAPY WITH STEREOTACTIC LOCALIZATION IN EARLY STAGE NON-SMALL CELL LUNG CANCER (NSCLC)
    Salvi, F.
    Donini, E.
    Baldissera, A.
    Degli Esposti, C.
    Martelli, O.
    Monari, F.
    Spagnolli, F.
    Frezza, G.
    Palombarini, M.
    Romagnoli, R.
    LUNG CANCER, 2009, 64 : S48 - S49
  • [36] Real-world biomarker testing trends in metastatic non-small cell lung cancer (NSCLC).
    Clinton, Natasha
    Patel, Manish R.
    Ayars, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E18728 - E18728
  • [37] CONCURRENT CHEMORADIATION (CCHRT) FOR STAGE III NON-SMALL CELL LUNG CANCER (NSCLC): A PHASE II STUDY FROM THE GALICIAN LUNG CANCER GROUP
    Casal, Joaquin
    Ponte, C.
    Senin, C.
    Campos, B.
    Firvida, Xl
    Carmona, M.
    Hernandez, E.
    Lopez, Md
    Formoso, I.
    Lazaro, M.
    Vazquez, S.
    Areses, Mc
    Rodriguez, C.
    Pena, C.
    Villanueva, Mj
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S849 - S849
  • [38] Neoadjuvant chemoradiation in non-small cell lung cancer
    Milleron, B.
    Girard, N.
    Gounant, V.
    Mornex, F.
    CANCER RADIOTHERAPIE, 2007, 11 (1-2): : 36 - 40
  • [39] Neoadjuvant chemoradiation in non-small cell lung cancer
    Girard, N.
    Hennequin, C.
    Mornex, F.
    ONCOLOGIE, 2007, 9 (06) : 475 - 481
  • [40] Third-generation drugs in the chemoradiation of stage III non-small cell lung cancer (NSCLC): A meta-analysis of efficacy and toxicity parameters
    Aydiner, A.
    Can, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345